INSIGHTS ON CELL & GENE OUTSOURCING ISSUES
-
How To Promote Batch-To-Batch Consistency In CAR-T Therapies
Patient immune cells and varied raw materials introduce inherent biological variability into CAR-T therapy manufacturing, making it a constant balancing act of adjusting processes and technology to minimize batch-to-batch variability.
-
Spent Media Analysis To Improve Cell Therapy Manufacturing
Targeted metabolomics-based PAT allows for metabolic profiling of the T-cells throughout the cell therapy manufacturing process through spent media analysis.
-
CTDMO Services To Fast-Track The Advancement Of mRNA-Based Drugs
Discover CTDMO services that establish robust, integrated, and consistent processes across all stages, enabling you to fast-track the advancement of your mRNA-based vaccines and therapeutics.
-
A CDMO’s Checklist For Prospective Clients: Part 3
In the last entry of our client checklist series, we delve into crucial aspects such as project management, decision-making, MSA negotiations, and building trust in CDMO-client partnerships.
-
A CDMO’s Checklist For Prospective Clients: Part 2
In Part 2 of our series, we delve deeper into the crucial elements of transparency that prospective clients should consider when partnering with a CDMO, including analytics, documentation, and more.
-
A CDMO’s Checklist For Prospective Clients: Part 1
Ever wondered about the flip side of client-CDMO dynamics? In this series, discover why transparency is vital for both parties in a fruitful partnership.
-
Lentiviral Vector CDMO Solutions
Learn how our expertise in high-yield suspension cell lines, robust lentiviral vector production, and extensive quality control measures can expedite your innovative lentiviral vector programs.
-
Emulate Contract Research Services
Understand and predict human response for your drug candidates with expert help. Explore contract research services for researchers seeking to harness the advantages of organ-on-a-chip technology.
-
Response To FDA Black Box Warning
The FDA has launched an investigation into the risk of T-cell malignancies following CAR-T cell immunotherapies. Review the key points of this announcement concerning the CGT research community.
-
How Community Oncologists View CAR T-Cell Therapy Possibilities And Challenges
Learn how a partner with innovative solutions aimed at overcoming the barriers that limit the real-world impact of CAR T-cell therapy can make these advanced therapies more accessible and affordable.